Winel Fonbah: Elevating Anticoagulation Literacy
Winel Fonbah, Registered Nurse at Regional hospital limbe, shared a post on LinkedIn:
“Elevating Anticoagulation Literacy: A Must-Know Guide for Clinicians!
Navigating the landscape of anticoagulants is fundamental for patient safety and effective treatment of conditions like AFib, DVT, and PE. I came across this excellent breakdown (shared below) and wanted to add some crucial context and clinical insights for my fellow healthcare professionals.
Anticoagulants: The Unsung Heroes of Cardiovascular Care.
In healthcare, few medication classes have as much impact on patient safety as anticoagulants, meds that prevent existing blood clots from getting bigger and stop new ones from forming.
While we often focus on the big names—Heparin, Warfarin (Coumadin), and newer Direct Oral Anticoagulants (DOACs)—what’s equally important is understanding how they differ, how they’re monitored, and how we keep patients safe.
Key Insights:
- Heparin: Fast-acting, short-term therapy; requires aPTT monitoring and has an antidote (Protamine sulfate). Watch for heparin-induced thrombocytopenia.
- Warfarin: Long-term therapy that needs consistent Vitamin K intake and regular INR monitoring, It has a slower onset, with antidotes including Vitamin K and FFP.
- DOACs: A newer class offering long-term protection with fewer monitoring requirements and fewer food interactions. Recently, more antidotes have been approved—making them even safer.
Across all anticoagulants, bleeding precautions remain essential, from avoiding aspirin to using soft toothbrushes and minimizing invasive procedures.
As clinicians, educators, or healthcare leaders, staying updated on these meds isn’t just knowledge—it’s patient safety.
Question for you:
- What’s one insight or tip you think every new nurse or healthcare student should know about anticoagulants?
Drop it in the comments—let’s build a resource together.”
Stay informed with Hemostasis Today.
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall
-
Jun 10, 2026, 17:51Mariam Swidan: Some Red Blood Cells Can’t Handle Pressure
-
Jun 10, 2026, 17:49Ankit Mathur: Hosting ISBT Academy Day on Rare Donor Program in India
-
Jun 10, 2026, 17:48Shadi Tabibian: When Patients Bleed but Standard Testing Is Normal